New brain MRI lesion activity was suppressed ( > @ % ) in the first @ weeks after ofatumumab administration ( all doses ) , with statistically significant reductions ( p < @ ) favoring ofatumumab found in new T@ gadolinium-enhancing lesions , total enhancing T@ lesions , and new and/or enlarging T@ lesions .